Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Nevirapine

FDA-approved product (tablet, oral), marketed as Nevirapine, Viramune, Viramune Xr.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Nevirapine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Non-nucleoside reverse transcriptase inhibitors
FDA pharmacologic class
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AG01

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli49.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis49.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Nevirapine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Nevirapine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • The Rilpivirine Cerebrospinal-fluid (CSF) Study

    NCT01562886 · start 2012-03

    Registered record
    Registry ID
    NCT01562886
    Conditions
    HIV
    Interventions
    Rilpivirine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-03
    Completion
    2013-02
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionRilpivirine
    PhasePhase 1
    Registry statusCompleted

  • Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

    NCT01495702 · start 2011-12

    Registered record
    Registry ID
    NCT01495702
    Conditions
    Acquired Immunodeficiency Syndrome; HIV Infections
    Interventions
    NNRTI; FTC/TDF; Stribild
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-12
    Completion
    2014-12
    Enrolment
    439

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcquired Immunodeficiency Syndrome; HIV Infections
    InterventionNNRTI; FTC/TDF; Stribild
    PhasePhase 3
    Registry statusCompleted

  • Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries

    NCT01061151 · start 2011-03-01

    Registered record
    Registry ID
    NCT01061151
    Conditions
    HIV Infections
    Interventions
    Zidovudine (ZDV); Nevirapine (NVP): Antepartum Mothers; Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]) tail; Lamivudine-Zidovudine (3TC-ZDV); Lopinavir-ritonavir (LPV-RTV); Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]); Nevirapine (NVP): Infant short-course; Nevirapine (NVP): Infant extended; No Intervention; Discontinue triple ARVs; Continue triple ARVs
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-03-01
    Completion
    2016-09-30
    Enrolment
    3,747

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionZidovudine (ZDV); Nevirapine (NVP): Antepartum Mothers; Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]) tail; Lamivudine-Zidovudine (3TC-ZDV) +7 more
    PhasePhase 3
    Registry statusCompleted

  • Influence of Nevirapine on HCV Viral Load

    NCT01277627 · start 2011-01

    Registered record
    Registry ID
    NCT01277627
    Conditions
    HCV Infection.; HCV Viral Load.
    Interventions
    Nevirapine; efavirenz, protease inhibitors
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2011-01
    Completion
    Not recorded
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHCV Infection.; HCV Viral Load.
    InterventionNevirapine; efavirenz, protease inhibitors
    PhaseNot applicable
    Registry statusUnknown

  • Effectiveness of Efavirenz-based Regimen in HIV-1-infected Patients With Nevirapine Hypersensitivity

    NCT01044810 · start 2010-01

    Registered record
    Registry ID
    NCT01044810
    Conditions
    Treatment Failure, HIV or AIDS; CD4 Cell Counts
    Interventions
    Efavirenz-based regimens
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-01
    Completion
    2010-03
    Enrolment
    559

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTreatment Failure, HIV or AIDS; CD4 Cell Counts
    InterventionEfavirenz-based regimens
    PhaseNot recorded
    Registry statusCompleted

  • HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children

    NCT00978068 · start 2009-09

    Registered record
    Registry ID
    NCT00978068
    Conditions
    Malaria; HIV Infections
    Interventions
    Lopinavir/Ritonavir (LPV/r); Nevirapine (NVP); Efavirenz (EFV); 2 nucleoside reverse transcriptase inhibitor (NRTI)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-09
    Completion
    2013-01
    Enrolment
    176

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria; HIV Infections
    InterventionLopinavir/Ritonavir (LPV/r); Nevirapine (NVP); Efavirenz (EFV); 2 nucleoside reverse transcriptase inhibitor (NRTI)
    PhasePhase 3
    Registry statusCompleted

  • Non-interventional Observational Study With Viramune (Nevirapine) and Various Drug Combinations in the Antiretroviral Combination Treatment of HIV-infected Patients Who Have Already Been Treated for Approx. 10 Years With Viramune

    NCT00979420 · start 2009-08

    Registered record
    Registry ID
    NCT00979420
    Conditions
    HIV Infections
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2009-08
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • TMC207-TiDP13-C117: Interaction Study in Human Immunodeficiency Virus-type 1 (HIV-1) Infected Patients With Nevirapine (NVP)

    NCT00910806 · start 2009-06

    Registered record
    Registry ID
    NCT00910806
    Conditions
    HIV Infections
    Interventions
    TMC207; nevirapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-06
    Completion
    2010-06
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionTMC207; nevirapine
    PhasePhase 1
    Registry statusCompleted

  • Switching Nevirapine Immediate Release( IR) Based Regimen to Nevirapine Extended Release (XR) Based Regimen in Human Immunodeficiency Virus One (HIV-1) Infected Patients

    NCT00819052 · start 2008-12

    Registered record
    Registry ID
    NCT00819052
    Conditions
    HIV Infections
    Interventions
    Nevirapine XR; Nevirapine XR; Nevirapine IR
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-12
    Completion
    2012-01
    Enrolment
    445

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionNevirapine XR; Nevirapine XR; Nevirapine IR
    PhasePhase 3
    Registry statusCompleted

  • Nevirapine vs Ritonavir-boosted Lopinavir in ART Naive HIV-infected Adults in a Resource Limited Setting

    NCT01772940 · start 2008-12

    Registered record
    Registry ID
    NCT01772940
    Conditions
    HIV-1 Infection
    Interventions
    nevirapine; ritonavir-boosted Lopinavir; Tenofovir/emtricitabine; Zidovudine/lamivudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-12
    Completion
    2011-12
    Enrolment
    425

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    Interventionnevirapine; ritonavir-boosted Lopinavir; Tenofovir/emtricitabine; Zidovudine/lamivudine
    PhasePhase 4
    Registry statusCompleted

  • Drug Interaction Between Coartem® and Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients

    NCT00620438 · start 2008-02

    Registered record
    Registry ID
    NCT00620438
    Conditions
    HIV Infections; Tuberculosis
    Interventions
    Lumefantrine-artemether and nevirapine; lumefantrine-artemether and efavirenz; Lumefantrine-artemether and rifampicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2008-02
    Completion
    2011-07
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Tuberculosis
    InterventionLumefantrine-artemether and nevirapine; lumefantrine-artemether and efavirenz; Lumefantrine-artemether and rifampicin
    PhasePhase 4
    Registry statusUnknown

  • Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146 CARINEMO)

    NCT00495326 · start 2007-12

    Registered record
    Registry ID
    NCT00495326
    Conditions
    Tuberculosis; Aids; Hiv Infections
    Interventions
    Nevirapine based therapy; Efavirenz based therapy; Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2007-12
    Completion
    2011-04
    Enrolment
    570

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Aids; Hiv Infections
    InterventionNevirapine based therapy; Efavirenz based therapy; Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z)
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Trizivir Vs. Kaletra and Combivir for the Prevention of Mother-to-Child Transmission of HIV

    NCT00270296 · start 2006-06

    Registered record
    Registry ID
    NCT00270296
    Conditions
    HIV Infections
    Interventions
    Trizivir; Lamivudine/Zidovudine; Lopinavir/Ritonavir; Nevirapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-06
    Completion
    2010-09
    Enrolment
    730

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionTrizivir; Lamivudine/Zidovudine; Lopinavir/Ritonavir; Nevirapine
    PhasePhase 2
    Registry statusCompleted

  • Safety and Efficacy of Two Once Daily Anti Retroviral Treatment Regimens Along With Anti-tuberculosis Treatment

    NCT00332306 · start 2006-06

    Registered record
    Registry ID
    NCT00332306
    Conditions
    Tuberculosis; Human Immunodeficiency Virus Infections
    Interventions
    Didanosine, Lamivudine, Efavirenz; Didanosine, Lamivudine, Nevirapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2006-06
    Completion
    2011-12
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Human Immunodeficiency Virus Infections
    InterventionDidanosine, Lamivudine, Efavirenz; Didanosine, Lamivudine, Nevirapine
    PhasePhase 3
    Registry statusUnknown

  • Pharmacokinetics Study on Nevirapine Resistance in Tanzania

    NCT00294892 · start 2006-02

    Registered record
    Registry ID
    NCT00294892
    Conditions
    HIV Infections
    Interventions
    carbamazepine and nevirapine; Nevirapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-02
    Completion
    2010-06
    Enrolment
    144

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    Interventioncarbamazepine and nevirapine; Nevirapine
    PhasePhase 2
    Registry statusCompleted